OHSU Researchers Secured $7.5 Million for Gene Therapy

The federal funding supports research into potential cures for rare kidney diseases through viral delivery.

Updated on Oct. 12, 2026 in Biotech

OHSU Researchers Secured $7.5 Million for Gene Therapy

Live Poll

Should the federal government increase funding for gene therapy research to cure rare diseases?

Oregon Health and Science University researchers received $7.5 million in federal funding across three grants to advance gene therapy for rare kidney conditions. This research-stage development aims to replace the current standard of symptom management with a curative approach.

Why it matters

The grant enables researchers to shift from managing chronic rare kidney diseases toward developing targeted genetic cures. It addresses a significant therapeutic gap, as these conditions currently lack any approved curative treatments.

The funding supports the refinement of methods to deliver healthy gene copies directly into diseased kidney cells using harmless viruses as transport vehicles. Benchmarks remain limited to early-stage efficacy demonstrations in mice and primates.

The players

Oregon Health and Science University

A Portland-based research institution focused on clinical medicine, biomedical research, and complex care delivery.

The details

The research focuses on gene therapy, a technique that replaces or supplements faulty genes with functional copies to correct cellular behavior. Researchers utilize harmless viruses as delivery vehicles—modified, inert viral shells that transport genetic material into target cells without causing infection. This approach is currently being evaluated in preclinical models, specifically mice and primates, to determine if the therapeutic genes can successfully integrate and restore normal kidney function.

Clinical trials for the therapy are planned to commence within the next four years.

The Tech Race

This project integrates into the broader NIH-funded gene therapy research pipeline currently targeting rare, monogenic disorders. It follows a pattern of academic centers seeking to translate genetic repair mechanisms into viable clinical interventions for historically incurable conditions.

This development remains in the preclinical phase and offers no immediate change for patients living with rare kidney diseases. If successful, the planned clinical trials will eventually provide the first data on safety and efficacy for human participants.

The takeaway

The project signals a shift toward addressing the underlying genetic causes of rare renal disorders rather than treating downstream symptoms. Observers should track the four-year milestone for clinical trial initiation as the primary indicator of the technology's move toward human viability.